Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss After Total Hip Replacement
Blood Loss, Surgical
About this trial
This is an interventional prevention trial for Blood Loss, Surgical focused on measuring Total hip replacement, Oral tranexamic acid, Oral aminocaproic acid, Blood loss
Eligibility Criteria
Inclusion Criteria:
- Age over 18 years
- Total replacement of the primary hip due to: 1) Primary Coxarthrosis, 2) Avascular hip necrosis, 3) Transcervical fracture
- Unilateral procedure
- Press-fit prosthesis
- Without the use of cement for the placement of the prosthesis
- Desire to participate voluntarily in the study and signature of informed consent
- Pre-operative assessment with result between ASA I, ASA II or ASA III performed and annexed in the clinical file either by the Department of Internal Medicine, Cardiology or Anesthesiology of our hospital.
- Possibility for oral administration of the drug.
Exclusion Criteria:
- History of thrombotic or embolic event in the last 6 months
- Clinical history of coagulopathy
- Previous surgeries in the hip to intervene
- Patients who have received aspirin, platelet or coumarinic antiplatelet agents in the week prior to surgery or NSAIDs two days prior to surgery.
- History of myocardial infarction, arteriopathy or unstable angina in the 12 months prior to surgery.
- Those patients whose preoperative assessment corresponds to an ASA IV or the procedure is contraindicated in its preoperative assessment.
- Revision hip replacement
- Tumoral hip replacement
- Bilateral hip replacement
- Cognitive deficit
- Patients who meet the inclusion criteria but do not wish to participate in the study
- Patients with a diagnosis of Terminal Chronic Kidney Disease or with a serum creatinine higher than 1.47 mg / dl in the preoperative laboratories.
- Patients with inability to ingest the drug orally.
- Patients who are pregnant or breast-feeding or who are taking oral contraceptives.
- Seizure history
- Hypersensitivity to the active substance or to any of the excipients
Sites / Locations
- Universidad Autonoma de Nuevo Leon
Arms of the Study
Arm 1
Arm 2
Active Comparator
Experimental
Tranexamic acid
Aminocaproic acid
Will be administered orally three times (administering 2 tablets each time). In the case of tranexamic acid are 650 mg each. The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water. For tranexamic acid a total dose of 3.9 grams (6 tablets) divided between the 3 administrations (1.3 grams each, ie 2 tablets of 650 mg) will be administered.
Will be administered orally three times (administering 2 tablets each time). In the case of aminocaproic tablets are 1000 mg each.The first administration will be two hours before the induction of anesthesia, the second 6 hours post-surgery and the third 12 hours after surgery. All by oral administration with a drink of water. The medicines will be administered with a volume of 40 ml of water. For the aminocaproic acid, a total dose of 6 grams (6 tablets) divided between the 3 administrations (2 gram each, ie 2 tablets of 1000 mg) will be administered.